TY - JOUR
T1 - The PREVENT dementia programme
T2 - baseline demographic, lifestyle, imaging and cognitive data from a midlife cohort study investigating risk factors for dementia
AU - Ritchie, Craig W
AU - Bridgeman, Katie
AU - Gregory, Sarah
AU - O’Brien, John T
AU - Danso, Samuel O
AU - Dounavi, Maria-Eleni
AU - Carriere, Isabelle
AU - Driscoll, David
AU - Hillary, Robert
AU - Koychev, Ivan
AU - Lawlor, Brian
AU - Naci, Lorina
AU - Su, Li
AU - Low, Audrey
AU - Mak, Elijah
AU - Malhotra, Paresh
AU - Manson, Jean
AU - Marioni, Riccardo
AU - Murphy, Lee
AU - Ntailianis, Georgios
AU - Stewart, William
AU - Muniz-Terrera, Graciela
AU - Ritchie, Karen
N1 - Funding: PREVENT is funded by the Alzheimer Society (grant numbers 178, 264 and 329), Alzheimer’s Association (grant number TriBEKa-17-519007) and philanthropic donations. Sub-studies have their own funding sources that are not detailed here. G.M.-T. acknowledges the support of the Osteopathic Heritage Foundation through funding for the Osteopathic Heritage Foundation Ralph S. Licklider, D.O., Research Endowment in the Heritage College of Osteopathic Medicine. I.K. declares support for the work on this project through the NIHR Oxford Biomedical Research Centre, Medical Research Council project as well as personal awards (National Institute for Health and Care Research (NIHR) Academic Lectureship and National Institute for Health and Care Research (NIHR) Development and Skills Enhancement award).
PY - 2024
Y1 - 2024
N2 - PREVENT is a multi-centre prospective cohort study in the UK and Ireland that aims to examine midlife risk factors for dementia and identify and describe the earliest indices of disease development. The PREVENT dementia programme is one of the original epidemiological initiatives targeting midlife as a critical window for intervention in neurodegenerative conditions. This paper provides an overview of the study protocol and presents the first summary results from the initial baseline data to describe the cohort. Participants in the PREVENT cohort provide demographic data, biological samples (blood, saliva, urine and optional cerebrospinal fluid), lifestyle and psychological questionnaires, undergo a comprehensive cognitive test battery and are imaged using multi-modal 3-T MRI scanning, with both structural and functional sequences. The PREVENT cohort governance structure is described, which includes a steering committee, a scientific advisory board and core patient and public involvement groups. A number of sub-studies that supplement the main PREVENT cohort are also described. The PREVENT cohort baseline data include 700 participants recruited between 2014 and 2020 across five sites in the UK and Ireland (Cambridge, Dublin, Edinburgh, London and Oxford). At baseline, participants had a mean age of 51.2 years (range 40–59, SD ± 5.47), with the majority female (n = 433, 61.9%). There was a near equal distribution of participants with and without a parental history of dementia (51.4% versus 48.6%) and a relatively high prevalence of APOEɛ4 carriers (n = 264, 38.0%). Participants were highly educated (16.7 ± 3.44 years of education), were mainly of European Ancestry (n = 672, 95.9%) and were cognitively healthy as measured by the Addenbrookes Cognitive Examination-III (total score 95.6 ± 4.06). Mean white matter hyperintensity volume at recruitment was 2.26 ± 2.77 ml (median = 1.39 ml), with hippocampal volume being 8.15 ± 0.79 ml. There was good representation of known dementia risk factors in the cohort. The PREVENT cohort offers a novel data set to explore midlife risk factors and early signs of neurodegenerative disease. Data are available open access at no cost via the Alzheimer’s Disease Data Initiative platform and Dementia Platforms UK platform pending approval of the data access request from the PREVENT steering group committee.
AB - PREVENT is a multi-centre prospective cohort study in the UK and Ireland that aims to examine midlife risk factors for dementia and identify and describe the earliest indices of disease development. The PREVENT dementia programme is one of the original epidemiological initiatives targeting midlife as a critical window for intervention in neurodegenerative conditions. This paper provides an overview of the study protocol and presents the first summary results from the initial baseline data to describe the cohort. Participants in the PREVENT cohort provide demographic data, biological samples (blood, saliva, urine and optional cerebrospinal fluid), lifestyle and psychological questionnaires, undergo a comprehensive cognitive test battery and are imaged using multi-modal 3-T MRI scanning, with both structural and functional sequences. The PREVENT cohort governance structure is described, which includes a steering committee, a scientific advisory board and core patient and public involvement groups. A number of sub-studies that supplement the main PREVENT cohort are also described. The PREVENT cohort baseline data include 700 participants recruited between 2014 and 2020 across five sites in the UK and Ireland (Cambridge, Dublin, Edinburgh, London and Oxford). At baseline, participants had a mean age of 51.2 years (range 40–59, SD ± 5.47), with the majority female (n = 433, 61.9%). There was a near equal distribution of participants with and without a parental history of dementia (51.4% versus 48.6%) and a relatively high prevalence of APOEɛ4 carriers (n = 264, 38.0%). Participants were highly educated (16.7 ± 3.44 years of education), were mainly of European Ancestry (n = 672, 95.9%) and were cognitively healthy as measured by the Addenbrookes Cognitive Examination-III (total score 95.6 ± 4.06). Mean white matter hyperintensity volume at recruitment was 2.26 ± 2.77 ml (median = 1.39 ml), with hippocampal volume being 8.15 ± 0.79 ml. There was good representation of known dementia risk factors in the cohort. The PREVENT cohort offers a novel data set to explore midlife risk factors and early signs of neurodegenerative disease. Data are available open access at no cost via the Alzheimer’s Disease Data Initiative platform and Dementia Platforms UK platform pending approval of the data access request from the PREVENT steering group committee.
KW - Risk factors
KW - Preclinical dementia
KW - Alzheimer’s disease
KW - Observational cohort
KW - Brain health
U2 - 10.1093/braincomms/fcae189
DO - 10.1093/braincomms/fcae189
M3 - Article
SN - 2632-1297
VL - 6
JO - Brain Communications
JF - Brain Communications
IS - 3
M1 - fcae189
ER -